CMPS: the FDA-stage shroom bet with actual Phase 3 data a.k.a shrooms to the moon
COMPASS Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression.
Serious fucking DD for you retards
- Both Phase 3 trials met their primary endpoints with statistically significant results.
- COMP360 has FDA Breakthrough Therapy designation and the company is progressing toward an NDA.
- If approved, it could become the first major regulated psilocybin treatment and own a very memeable category.
- The stock still offers serious upside if approval and commercial adoption land. Which it fucking will.
Kevin Mak, the legend who was early on both SPHR and (unnamed ass-tits satellite stock) is in. And that's enough for me.
Disclosure: NFA, I'm in for 4000 shares at $13.45